Dr Pablo Barrio talks about treatment in schizophrenia

Dr Pablo Barrio, Spain talks about what to tell patients about their condition and discusses quality of life issues, treatment and more.

Q. When you first tell a patient they have schizophrenia, do you tell them this is a lifelong condition?

A. Patients aren’t told immediately although they are told they will have long-term treatment needs. It is left vague in order not to make it sound like a life sentence.

Q. Having made a diagnosis of schizophrenia – do you tell patients at that point how long they are likely to need to be on medication?

A. Yes. Patients are told they are likely to be on medication for 3 to 5 years. We usually try to present it as “at least three years”.

Q. What factors have a large contribution to the quality of life of a patient with schizophrenia?

A. Symptom severity, especially negative symptoms, drug side-effects, family support and community resources all contribute to the quality of life of a patient with schizophrenia.

Q. What methods do you employ to preserve or improve the quality of life of your patients with schizophrenia?

A. Medication is the psychiatrist’s responsibility and we need to balance efficacy with side-effects in order to ensure compliance with therapy. For other therapies, it depends on the resources available. A rehabilitation clinic would be made use of, if appropriate. 

Q. Do you think of schizophrenia as a neurodevelopmental disorder or as a neurodegenerative disease?

A. It’s both. There are genetic components with environmental triggers. It’s a multicomponent condition and it’s likely that schizophrenia comprises several diseases.

Q. What proportion of patients with schizophrenia have the potential to achieve improvements in relationships?

A. Optimistically, maybe 30%.

The views and opinions expressed on this page do not necessarily reflect those of Otsuka and Lundbeck.
Country selection
We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil
You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente agli Operatori Sanitari (medici e farmacisti). I contenuti di questo sito sono prodotti da un team di Operatori Sanitari il cui obiettivo è presentare le ultime novità in ambito psichiatrico e neurologico, attraverso interviste, registrazioni audio/video di seminari con opinion leader, report e sintesi di congressi sia internazionali che nazionali. Per poter accedere al sito è quindi necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Operatore Sanitario.
Hello
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Congress
Register for access to Progress in Mind in your country